Appointment of Executive Chairman at ADAM

RNS Number : 7380G

Advanced Oncotherapy PLC

24 November 2015

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Appointment of Executive Chairman at ADAM

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Professor Steve Myers OBE, Head of Medical Applications at CERN, has been appointed as Executive Chairman of Advanced Oncotherapy's fully owned subsidiary ADAM S.A ("ADAM").

ADAM was founded in 2007 as a spin-off from CERN, the European Organisation for Nuclear Research, and was acquired by Advanced Oncotherapy in 2013. The ADAM team is responsible for designing and developing the Company's next-generation proton beam cancer therapy technology, the LIGHT system.

Professor Myers has been the Head of Medical Applications at CERN in Geneva since 2014. From 2009-2013, he was the Director of Accelerators and Technology, where he was responsible for the operation and exploitation of the whole accelerator complex, with particular emphasis on the Large Hadron Collider ("LHC") and for the development of the new projects and technologies.

In 2012, he was elected as a Fellow of the Royal Academy of Engineering which honours the UK's most eminent engineers, and is a Fellow of the Institute of Physics, the European Physical Society and International Fellow of the American Physical Society. He is internationally recognised for his engineering contributions and leadership in the development of CERN's particle colliders over the past 40 years, including the Intersecting Storage Ring Accelerator, the Large Electron-Positron collider and the LHC.

Professor Myers has been awarded a number of international prizes including the Duddel Prize & Medal from the Institute of Physics (now re-named the Gabor Medal & Prize) and was awarded an OBE in 2013 for services to science and technology. Professor Myers holds a number of honorary and advisory positions and is Chair of the Advisory Committees of both the John Adams Accelerator Institute in Oxford and the Cockroft Accelerator Institute and has published over 300 scientific papers.

Sanjeev Pandya, CEO of Advanced Oncotherapy commented: "Professor Myers' wealth of knowledge and experience is second to none. He has been part of the CERN Scientific Review Board since its inception in January 2015 and has provided the Company with invaluable advice and high level guidance during this time. We are extremely lucky to have someone of his calibre on board and we are looking forward to working more closely with Steve in the future."

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya, CEO	Tel: [phone]
Nicolas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: [phone]
Beaufort Securities (Joint Broker)
Jon Levinson / Elliot Hance	Tel: [phone]
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a fraction of the size and significantly lower in cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

The Company has signed two purchase agreements with Sinophi Healthcare Limited for the LIGHT proton therapy systems to be installed in hospitals in China. There are also four additional framework agreements and further Letters of Intent from other healthcare providers.

The Company has also signed a joint venture agreement with CircleHealth, owned by AIM-listed Circle Holdings plc to operate the Company's proton beam cancer therapy centre in Harley Street.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

BOAUSVBRVVAAURA